October 2, 2025Frontiers in Cell and Developmental BiologyOpen Access

Advances in precision oncology using patient-derived organoids and functional biomaterials

View Full Paper

Ask AI

Bookmark

Patient-derived organoids enhance tumor modeling and therapeutic response assessment, addressing cancer heterogeneity.
Integration of organoids with functional biomaterials improves predictive power in therapeutic strategies for cancer.
Emerging PDO biobanks and co-culture systems provide essential tools for advancing personalized cancer therapy.
Biomarker discovery linked with patient-specific variability can guide effective treatment options against drug resistance.

Discussion

No takes yet. Share an insight, caveat, or question.

Implication

This review uncovers how patient-derived organoids model tumor heterogeneity in cancer therapy, suggesting integration with functional biomaterials enhances therapeutic prediction.

Cite This Study

Singh et al. (2025) studied this question.

synapsesocial.com/papers/68de84b65b556a9128e1b545 https://doi.org/10.3389/fcell.2025.1670328

View Full Paper

Ask AI

Bookmark

Implication

This review uncovers how patient-derived organoids model tumor heterogeneity in cancer therapy, suggesting integration with functional biomaterials enhances therapeutic prediction.

Advances in precision oncology using patient-derived organoids and functional biomaterials

Key Points

Discussion

Implication

Cite This Study

Advances in precision oncology using patient-derived organoids and functional biomaterials

Key Points

Discussion

Implication

Cite This Study

Keep reading

Keep reading